All In Biotech

Drug Trial Radar · NCT06332170

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

ARTEMIS-101: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of HS-20093 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

610

Planned (sponsor's estimate)

Start

Apr 26, 2024

Primary completion

May 30, 2026

Study completion May 30, 2028

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Mar 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients.

Conditions

  • Advanced Solid Tumor

Interventions

  • HS-20093Drug

    administered as an IV infusion

  • AdebrelimabDrug

    administered as an IV infusion

  • Cisplatin/ CarboplatinDrug

    administered as an IV infusion

  • CetuximabDrug

    administered as an IV infusion

  • EnzalutamideDrug

    160mg once daily (QD) orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) for combination-treatmentsTime frame: Up to day 21 from the first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.